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Background: Comprehensive care in homozygous sickle cell disease (HbSS) entails universal neonatal screening
and subsequent monitoring of identified patients, a process which has been streamlined in the neighbouring island
of Jamaica. In preparation for a similar undertaking in Barbados, we have developed a database of persons with
known HbSS, and have piloted processes for documenting clinical manifestations. We now present a brief clinical
profile of these findings with comparisons to the Jamaican cohort.
Methods: HbSS participants were recruited from clinics and support groups. A history of select clinical symptoms
was taken and blood and urine samples and echocardiograms were analysed. A re-analysis of data from a previous
birth cohort was completed.
Results: Forty-eight persons participated (32 F/16 M); age range 10–62 yrs. 94% had a history of ever having a painful
crisis. In the past year, 44% of participants had at least one crisis. There were >69 crises in 21 individuals; 61% were
self-managed at home and the majority of the others were treated and discharged from hospital; few were admitted.
The prevalence of chronic leg ulceration was 27%. Forty-two persons had urinalysis, 44% were diagnosed with albuminuria
(urinary protein/creatinine ratio ≥30 mg/g). Thirty-two participants had echocardiography, 28% had a TRJV≥ 2.5 m/s.
Re-analysis of the incidence study revealed a sickle gene frequency (95% CI) of 2.01% (0.24 to 7.21).
Conclusion: Although we share a common ancestry, it is thought that HbSS is less common and less severe in Barbados
compared to Jamaica. The Jamaican studies reported a sickle gene frequency of 3.15 (2.81 to 3.52); the prevalence of
chronic leg ulcers and albuminuria was 29.5% and 42.5% respectively. These comparisons suggest that our initial thoughts
may be speculative and that HbSS may be an underestimated clinical problem in Barbados. A prospective neonatal
screening programme combined with centralized, routine monitoring of HbSS morbidity and outcomes will definitively
answer this question and will improve the evidence-based care and management of HbSS in Barbados.
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The clinical features of Homozygous Sickle Cell Disease
(HbSS) may be acute or chronic and are unpredictable
and sometimes life threatening [1-6]. Childhood interven-
tions such as blood transfusion therapy for stroke preven-
tion and prophylactic oral penicillin for sepsis have
reduced the incident risk of these complications [7,8].
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reproduction in any medium, provided the orand regular follow-up; in the case of HbSS this translates
to newborn screening, followed by a comprehensive care
regime for identified patients [9-13].
Barbados is a Caribbean island of 166 square miles and
a population of 289,000 persons [14]. 93% are of African
origin. Malaria is not endemic. Locally relevant data on
HbSS is restricted to a 10 year audit of the discharge diag-
nosis and morbidity in paediatric patients; and a single
neonatal screening programme of 997 consecutive births.
Re-analysis of the neonatal dataset reveals an HbSS geno-
type incidence of 2.01 (95% confidence interval 0.24 to
7.21) per 1,000 live births [15,16].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Clinical features associated with HbSS in the





n/N (%) n/N (%)
Ever painful crisis 45/48 (94) n/a
# participants who had≥ 1 pain crisis
in the last year
21/48 (44) 216/1160 (18.6)
• 1 crisis 5/21 (24) 119/216 (55.1)
• 2 crises 4/21 (19) 42/216 (19.4)
• 3 crises 1/21 (5) 21/216 (9.7)
• 4 crises 2/21 (9) 16/216 (7.4)
• ≥5 crises 9/21 (43) 18/216 (8)




Hx chronic leg ulcer 13/48 (27) 53/225 (29.5)
Albuminuria: (urinary protein/creatinine
ratio of >30 mg/g)
19/42 (44) 36/85 (42.5)
TRJV≥ 2.5 m/s 9/32 (28) n/a
This table shows a) the number (%) of the population who have ever
experienced a painful crisis b) the number (%) of the population who
experienced a painful crisis within the last year c) the frequency of crises
within the last year d) the number of painful crises per person in the last year
e)the number (%) of persons with a history of chronic leg ulceration f) the
number (%) of persons with albuminuria defined as urine albumin/creatinine
ratio of ≥30 mg/g and g) the number (%) of persons with a TRJV ≥2.5 m/s.
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den – both in terms of incidence and morbidity - is less
in the Barbadian than in the neighbouring Jamaican
population. Jamaica has a well-established cohort with
an HbSS genotype incidence of 3.15 (2.81 to 3.52) per
1000 live births reported from the 100,000 Jamaican ne-
onates screened between 1973 and 1981. Hence there is
currently no evidence that a higher incidence of HbSS
exists in Jamaican [9,16].
The aim of this study is two-fold. Firstly, because of
the overwhelming international evidence for the benefi-
cial effects of birth screening and subsequent compre-
hensive care, we aim to implement these cornerstones of
SCD clinical care in Barbados. This data-basing effort
will be the first step in developing the monitoring infra-
structure. Secondly, these data provide the initial preva-
lence of select clinical features for comparison to the
Jamaican counterparts.
Methods
Ethical approval was granted by the Ministry of Health/
University of the West Indies Institutional Review Board.
Research was carried out in accordance to the Declaration
of Helsinki. Persons with known HbSS were recruited
from public and private haematology clinics and support
groups. HbSS would have been diagnosed by acid-based
haemoglobin electrophoresis at the haematology depart-
ment of the Queen Elizabeth Hospital – the island’s only
public hospital. Informed, signed consent was obtained
from adult participants; for children assent was obtained
in addition to parental consent. A history of chronic leg
ulceration, pulmonary hypertension (pHTN), renal com-
promise, and the number of painful crises, as defined by
the individual participant, in the previous 12 months was
recorded. A history of co-morbid condition was also re-
corded. A single blood sample was taken from each par-
ticipant for haemoglobin, reticulocute count and LDH,
and urine samples were used to determine albumin/cre-
atinine ratio. Tricuspid regurgitant jet velocity (TRJV) was
obtained by echocardiography.
Results
Forty-eight persons with homozygous sickle cell disease
(HbSS) participated. There were 32 females and 16 males
aged 10–62 years. Blood results were mean (SD); haemo-
globin 7.6 (1.3) g/dl, reticulocyte count 11 (3.9) % and
LDH 646 (242) U/L.
A history of select clinical features revealed that forty-
five of the 48 persons (94%) had a history of ever having a
painful crisis. In the past year, 21 (44%) of participants had
at least one crisis; single crises occurred in 5 (24%), 2 cri-
ses in 4 (19%), 3 in 1 (5%), 4 in 2 (9%) and ≥5 in 9 (43%)
(Table 1). Cumulatively, there were more than 69 crises in
21 individuals in the past year; 61% (n = 42) were managedat home, the majority of the others were treated in Acci-
dent and Emergency (A&E) and discharged; few were ad-
mitted to hospital. Thirteen participants (27%) had a
history of chronic leg ulceration. Forty-two persons had
urinalysis, of these 19 (44%) were assigned as having renal
compromise as defined by a urinary protein/creatinine ra-
tio of >30 mg/g; at least 16% had macro-albuminuria
(urinary protein/creatinine ratio of >300 mg/g). Thirty-
two participants had echocardiograms, 9 (28%) of the re-
ports revealed a TRJV of ≥2.5 m/s (Table 1).
Discussion
Internationally, neonatal screening followed by compre-
hensive follow-up has greatly improved the knowledge
and evidence-based interventions in HbSS. This has led
to a decrease in the morbidity and mortality due to this
condition [9,10,17].
To date, local data is restricted to the HbSS population
incidence, however the statistical uncertainty of the
Barbados incidence estimates means that the conclusion
that the SS incidence at birth in Barbados was lower
than that reported in Jamaica was incorrect [9,16]. Lar-
ger neonatal screening samples are needed to estimate
genotype incidence with greater precision.
The acute painful crisis is the most common reason
for hospital visits in all age groups [18]. The percentage
of patients needing pharmacological intervention for
painful crises over the last year in our population was
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day-care management centre– 47% vs. 18.6% respectively
[19]. This disparity may be a reflection of our participant
profile. In the Barbadian study the entire cohort was asked
about a history of painful crisis; however in the Jamaican
cohort, only those who sought medical attention for their
crises were included; from our report, one-third of parti-
cipants managed their last crisis at home, these would not
have been included in the Jamaican report. From our pilot
data we can expect repeat crises in the majority of the
population, much like the Jamaican experience; however
only the minority of crises are actually treated as in-
hospital patients. This data may inform decisions on
the possibility of instituting a day-care facility for pain
management in Barbados.
Although not associated with mortality, the morbidity
associated with chronic leg ulcers is significant [20-22].
Anecdotally, it has been suggested that leg ulceration
among people with sickle cell disease are a rarity in the
Barbadian population however our prevalence (27%) is
similar to the 29.5% of the Jamaican cohort [23].
Proteinuria is a common finding in adults with homozy-
gous sickle cell disease and has been reported in young
children as well [4,24]. This can progress to nephrotic syn-
drome and renal failure, which would be expected to place
additional stress on our nephrology services and also car-
ries significant mortality [25]. The prevalence of protein-
uria in our population (44%) is similar to the 42.5% of the
Jamaican cohort [26].
With the increased life expectancy of persons with
HbSS, we are seeing end organ damage such as pHTN
[17,27]. Echocardiography is used as a screening tool for
pHTN; an elevated TRJV on echocardiography carries
significant mortality with the rate ratio for death being
10:1 in persons with SCD with vs. without [2]. This, plus
the inadequacy of treatment modalities makes it a worri-
some complication. The prevalence of which was 28%,
midway between that of the Nigerian population (25%)
and the US cohort (32%) [2,28]. There were no Jamaican
data available for comparison. This information may in-
form the decision to include echocardiography in rou-
tine HbSS screening.
Future studies in this population must also include
SCD haplotypes. The Barbadian and Jamaican populations
share a common African ancestry due to forced migration
during the trans-Atlantic slave trade [29,30]. Slaves were
initially sourced from Senegambia and the Windward
Coast where the Senegal and Benin haplotypes arose
respectively; and later from West-central Africa where the
Bantu haplotype is predominant. The haplotypes each
carry a different clinical risk [25,31-33]. Generally, the
Senegal haplotype is associated with preserved HbF and
milder disease whereas the Bantu haplotype is associated
with a more severe clinical picture. The Benin haplotype isintermediate in terms of clinical severity [25,28,34]. Recent
data shows that 76% of Jamaicans with SCD carry the
Benin haplotype and the associated clinical features are
also well documented [35].Based on the similarities in the
prevalence of morbidity among HbSS patients attending
clinics in Barbados and Jamaica, and the likelihood that we
share a common West African ancestry, one can hypo-
thesise that the Benin haplotype would also be preva-
lent in Barbados. However, genetic analysis is needed for
verification.
Conclusion
Anecdotally, it is believed that HbSS is less common with
symptoms that are less severe in Barbados compared to
Jamaica. This report suggests that those beliefs may be un-
founded and that HbSS may be an underestimated clinical
problem in Barbados. The Jamaican cohort studies which
included neonatal screening and centralized data-basing of
routine clinical follow-up, have contributed immensely to
the knowledge and management of Sickle cell disease in
that population. A similar structure will allow us to make
a definitive comparison between the two populations and
will improve the evidence-based care and management of
HbSS in Barbados.
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